{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:46:38Z","timestamp":1787013998071,"version":"build-2736575974"},"reference-count":35,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Experimental Allergy"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Current biologic therapies target allergic, eosinophilic or type 2 inflammation phenotypic asthma. However, frequency and degree of overlap among these subtypes is unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To characterize overlap among allergic, eosinophilic and type 2 asthma phenotypes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Post hoc analyses of baseline data were performed in two adult populations: (a) not selected for any asthma subtype (N\u00a0=\u00a0935) and (b) selected for allergic asthma (N\u00a0=\u00a01049). Degree of overlap was examined using commonly accepted phenotypic definitions to guide treatment for allergic asthma (skin prick\u2013positive and\/or positive serum\u2013specific immunoglobulin E\u00a0&gt;\u00a00.35 kU\/L) and eosinophilic asthma (blood eosinophil high count \u2265 300 cells\/\u00b5L; low cut\u2010off \u2265 150 cells\/\u00b5L). Consistent with previous studies, fractional exhaled nitric oxide high level of \u2265 35\u00a0ppb and low cut\u2010off of \u2265 25\u00a0ppb were selected as local markers of type 2 inflammation and to prevent overlap with the systemic eosinophilic asthma definition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the non\u2010subtype\u2013selected population, 78.0% had allergic asthma; of these, 39.5% had eosinophilic asthma and 29.5% had type 2 asthma. Within patients with eosinophilic asthma (40.6% of total), 75.8% had allergic asthma and 41.3% had type 2 asthma. Within patients with type 2 asthma (28.3% of total), 81.1% had allergic asthma and 59.2% had eosinophilic asthma. In the allergic asthma\u2013selected population, 38.3% had eosinophilic asthma and 29.2% had type 2 asthma. Within patients with eosinophilic asthma, 46.3% had type 2 asthma. Within patients with type 2 asthma, 60.8% had eosinophilic asthma. Overlaps among subtypes increased at low cut\u2010off values.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and clinical relevance<\/jats:title>\n                    <jats:p>In this post hoc analysis in adults with moderate\u2010to\u2010severe asthma, allergic asthma was the most prevalent phenotype, followed by eosinophilic and type 2 asthma. Despite observed overlaps, a considerable proportion of patients had only a predominantly allergic subtype. Understanding the degree of overlap across phenotypes will help patient management and guide treatment options.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/cea.13790","type":"journal-article","created":{"date-parts":[[2020,11,21]],"date-time":"2020-11-21T01:41:32Z","timestamp":1605922892000},"page":"546-555","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Overlap of allergic, eosinophilic and type 2 inflammatory subtypes in moderate\u2010to\u2010severe asthma"],"prefix":"10.1111","volume":"51","author":[{"given":"Meng","family":"Chen","sequence":"first","affiliation":[{"name":"Southwest Asthma and Allergy Associates Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"II","given":"Kirk","family":"Shepard","sequence":"additional","affiliation":[{"name":"University of South Florida Tampa FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Yang","sequence":"additional","affiliation":[{"name":"Genentech, Inc. South San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranil","family":"Raut","sequence":"additional","affiliation":[{"name":"Genentech, Inc. South San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hooman","family":"Pazwash","sequence":"additional","affiliation":[{"name":"Genentech, Inc. South San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile T.J.","family":"Holweg","sequence":"additional","affiliation":[{"name":"Genentech, Inc. South San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Choo","sequence":"additional","affiliation":[{"name":"University of California San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,1,7]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(13)70288-1"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/17476348.2018.1403318"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/879783"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.57.7.643"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0000000000000225"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000440"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2678"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/cea.12963"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.11.639"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2013.00046"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01824-2014"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2013.02.018"},{"key":"e_1_2_9_14_1","first-page":"CD011440","article-title":"Exhaled nitric oxide levels to guide treatment for adults with asthma","volume":"9","author":"Petsky HL","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/1177271919826550"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2015.10.027"},{"key":"e_1_2_9_17_1","unstructured":"Global Initiative for Asthma.Global strategy for asthma management and prevention (2018 update).www.ginasthma.org. Accessed 27 May 2020"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2006.03.031"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S109489"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2017.1392425"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.13302"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2018.04.043"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2014-206719"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(16)30265-X"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-154-9-201105030-00002"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2017.09.056"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60988-X"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31324-1"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.233"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2018.01.031"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2014.06.013"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2018.04.003"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2013.11.037"},{"key":"e_1_2_9_34_1","first-page":"A6473","article-title":"Baseline IgE levels as a marker of type 2 asthma among patients enrolled in the Prospective Observational Study to Evaluate Predictors of Clinical Effectiveness in Response to Omalizumab (PROSPERO)","volume":"193","author":"Chipps BE","year":"2020","journal-title":"Am J Crit Care Med"},{"key":"e_1_2_9_35_1","unstructured":"Xolair [prescribing information]. South San Francisco CA: Genentech Inc.;2019."},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200903-0392OC"}],"container-title":["Clinical &amp; Experimental Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cea.13790","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cea.13790","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cea.13790","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T10:49:10Z","timestamp":1693565350000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cea.13790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,7]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10.1111\/cea.13790"],"URL":"https:\/\/doi.org\/10.1111\/cea.13790","archive":["Portico"],"relation":{},"ISSN":["0954-7894","1365-2222"],"issn-type":[{"value":"0954-7894","type":"print"},{"value":"1365-2222","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,7]]},"assertion":[{"value":"2020-06-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}